focus -WSS

focus

author：focus 2025-09-30 00:49:46 - browse：484

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： After traumatic brain injury, life support decisions can use more time

entertainment

hotspot

WSS

H5N1 bird flu found in pasteurized milk: what we know

Removing probiotics from the NICU could threaten preemies' health

UnitedHealth financials solid despite Change Healthcare cyberattack

Just how powerful is the placebo effect?

H5N1 bird flu found in pasteurized milk: what we know

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

leisure time

focus

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why rehabilitation engineers need to center patients in their research

Apple is now the first public company to be valued at $3 trillion

MoonLake credibility takes another hit with mid

Medicare details structure of new drug price negotiation program

Just how powerful is the placebo effect?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UCSF medical school apologizes for unethical prisoner experiments

Bright Health sells Medicare Advantage business to Molina

UCSF medical school apologizes for unethical prisoner experiments

Wikipedia

More doctors should go into startup world

Diversity in clinical trials starts with building trust, experts say

Cholera vaccine supply gets boost as demand surges globally

Sanofi CEO defends move to abandon profit guidance, boost research

Ambulance rides for just $100? Advisers want major billing fixes

MultiPlan and major insurers sued for alleged medical price

explore

entertainment

hotspot

entertainment